Legend Biotech Faces Profit Crisis: Stock Slumps, Cell‑Therapy Challenges, and Investor Uncertainty
Legend Biotech’s cell‑therapy venture faces steep financial hurdles, with a negative P/E and volatile stock price, raising concerns for investors and industry analysts.
2 minutes to read